12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Depomed, Nautilus Neurosciences sales and marketing update

Depomed gained U.S. rights to Cambia diclofenac oral solution for migraines from Nautilus. Nautilus will receive $48.7 million in cash up front and will be eligible for up to $5 million in milestones on net sales. On a conference call to discuss the deal,...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >